These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 11362209

  • 1. AZT plus 3TC produces best results to date.
    Grodeck B.
    Posit Aware; 1995; ():6. PubMed ID: 11362209
    [Abstract] [Full Text] [Related]

  • 2. AZT studies reinforce benefits of combination.
    AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
    [Abstract] [Full Text] [Related]

  • 3. Three-drug combos.
    Posit Aware; 1996 Jan; 7(1):6. PubMed ID: 11363125
    [Abstract] [Full Text] [Related]

  • 4. Triple combination superior to double combination.
    Grodeck B.
    Posit Aware; 1995 Jan; ():6. PubMed ID: 11362210
    [Abstract] [Full Text] [Related]

  • 5. Nevirapine triple combo results released.
    Common Factor; 1995 Apr; (no 10):21. PubMed ID: 11362346
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006 Apr; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 8. Merck protease inhibitor: more news from Retroviruses Conference.
    James JS.
    AIDS Treat News; 1996 Feb 16; (no 241):1-3. PubMed ID: 11363186
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb 01; 8(2):141-51. PubMed ID: 7530585
    [Abstract] [Full Text] [Related]

  • 11. 3TC/AZT: just another combination.
    GMHC Treat Issues; 1995 Dec 01; 9(12):2. PubMed ID: 11362997
    [Abstract] [Full Text] [Related]

  • 12. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.
    Antivir Ther; 2004 Apr 01; 9(2):197-204. PubMed ID: 15134181
    [Abstract] [Full Text] [Related]

  • 13. Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
    James JS.
    AIDS Treat News; 1995 Dec 22; (no 237):3. PubMed ID: 11363075
    [Abstract] [Full Text] [Related]

  • 14. ACTG 175 and Delta.
    Torres G.
    GMHC Treat Issues; 1995 Oct 22; 9(10):2-3. PubMed ID: 11362915
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy increases survival.
    Treat Rev; 1995 Nov 22; (no 20):2-3. PubMed ID: 11363019
    [Abstract] [Full Text] [Related]

  • 16. Nevirapine surprise.
    Smart T.
    GMHC Treat Issues; 1996 Nov 22; 10(6/7):25. PubMed ID: 11363640
    [Abstract] [Full Text] [Related]

  • 17. Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
    Cooper EC.
    AMFAR Rep; 1996 Jan 22; ():1-5. PubMed ID: 11363617
    [Abstract] [Full Text] [Related]

  • 18. New combo trial/same old style.
    Gilden D.
    GMHC Treat Issues; 1995 Apr 22; 9(4):9. PubMed ID: 11362369
    [Abstract] [Full Text] [Related]

  • 19. Studies confirm value of early and combination treatments.
    Vazquez E.
    Posit Aware; 1995 Apr 22; VI(6):8. PubMed ID: 11363148
    [Abstract] [Full Text] [Related]

  • 20. Lamivudine (3TC) approved for combination use with AZT.
    James JS.
    AIDS Treat News; 1995 Dec 01; (no 236):1-5. PubMed ID: 11363049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.